Kange Corp.
KGNR
Other OTC2.20
USD
- -
- -
CIK
0001593773
ISIN
US4841991049
CUSIP
484199104
Return %
Stock
S&P500
1Y
57.14
26.53
3Y
1,000.00
76.60
5Y
131.58
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Arthur Malone Jr.
- Sector
- Technology
- Industry
- Software - Application
- Address
- 11724 Ventura Boulevard Studio City CA United States of America 91604
- IPO Date
- Jun 9, 2015
- CIK
- 0001593773
- Similar Companies
- Business
- Kange Corp operates as a start-up technology company focused on the development and commercialization of mobile software products tailored initially for the European market, specifically Estonia. Founded in 2017 and headquartered in Estonia, Kange Corp specializes in the intersection of advanced technology and holistic health treatments, with an emphasis on addressing neurological health issues such as PTSD, early-onset dementia, and Alzheimer’s disease, particularly in professional athletes. Its product offerings include software applications and treatment formulation services designed to support health management in these areas. The company also holds rights and interests in advanced database technology, specifically ElephantSqlDB®, which leverages artificial intelligence and quantum computing capabilities through proprietary algorithms like Grover’s Algorithm. Recent strategic developments for Kange Corp include a February 2023 letter of intent to acquire assets from Blabeey, enhancing its technology offerings in social media applications related to neurological conditions such as autism and PTSD. Additionally, in July 2024, Kange Corp entered into a revenue-sharing agreement linked to contracts involving Medicare enrollees and life and annuity insurance sales, facilitating new revenue streams. The company is actively exploring business expansions in the holistic health industry and related technological solutions. Furthermore, Kange Corp is exploring a potential acquisition aligned with EQ Labs, Inc. to strengthen the market position of the Last Shot® brand, which emphasizes sports health products and services. These efforts reflect a strategic shift toward integrating technology-driven health treatments with broader healthcare and insurance sectors across Europe and potentially North America. Kange Corp operates fundamentally within the technology and healthcare segments, targeting professional athletes and patients requiring specialized neurological health treatments, along with broader insurance and Medicare customer bases. The company’s operations encompass software development for health treatment modeling, technology consulting, and database innovation leveraging AI and quantum-computing advances. Its headquarters in Estonia supports its initial European market focus, with ongoing efforts to expand geographically and operationally through partnerships and acquisitions. This corporate profile highlights Kange Corp's core products of mobile health-related software and database technologies, recent asset acquisition to broaden its product scope, strategic revenue-sharing contracts, and ongoing pursuits to enhance its positioning in holistic health and sports-related neurological treatment markets. The company’s defining attributes include its advanced technological base, focus on neurological and holistic health solutions, and recent maneuvers to leverage alliances and acquisitions for growth and diversification.